Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Shares Outstanding (2016 - 2025)

Dexcom (DXCM) has disclosed Shares Outstanding for 13 consecutive years, with $98.1 million as the latest value for Q1 2022.

  • On a quarterly basis, Shares Outstanding rose 1.45% to $98.1 million in Q1 2022 year-over-year; TTM through Mar 2022 was $98.1 million, a 1.45% increase, with the full-year FY2021 number at $97.0 million, up 0.94% from a year prior.
  • Shares Outstanding was $98.1 million for Q1 2022 at Dexcom, up from $97.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $98.1 million in Q1 2022 to a low of $88.1 million in Q1 2018.
  • A 5-year average of $93.3 million and a median of $92.3 million in 2020 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 4.92% in 2020, then grew 0.94% in 2021.
  • Dexcom's Shares Outstanding stood at $90.0 million in 2018, then increased by 1.78% to $91.6 million in 2019, then grew by 4.91% to $96.1 million in 2020, then rose by 0.94% to $97.0 million in 2021, then rose by 1.13% to $98.1 million in 2022.
  • Per Business Quant, the three most recent readings for DXCM's Shares Outstanding are $98.1 million (Q1 2022), $97.0 million (Q4 2021), and $96.9 million (Q3 2021).